Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials

Publication date: November 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 11Author(s): Shalender Bhasin, Susan S Ellenberg, Thomas W Storer, Shehzad Basaria, Marco Pahor, Alisa J Stephens-Shields, Jane A Cauley, Kristine E Ensrud, John T Farrar, David Cella, Alvin M Matsumoto, Glenn R Cunningham, Ronald S Swerdloff, Christina Wang, Cora E Lewis, Mark E Molitch, Elizabeth Barrett-Connor, Jill P Crandall, Xiaoling Hou, Peter PrestonSummaryBackgroundThe Physical Function Trial (PFT) was one of seven Testosterone Trials (TTrials), the aim of which was to assess the effect of testosterone on mobility, self-reported physical function, falls, and patient global impression-of-change (PGIC) in older men with low testosterone concentrations, self-reported mobility limitation, and walking speed of less than 1·2 m/s. Using data from the PFT and the overall TTrials study population, we also aimed to identify whether the effect of testosterone on mobility differed according to baseline walking speed, mobility limitation, or other participant-level factors.MethodsThe TTrials included 790 men aged 65 years or older and with an average of two total testosterone concentrations below 275 ng/dL (9·5 nmol/L), of whom 390 had mobility limitation and a walking speed below 1·2 m/s and were enrolled in the PFT. Participants were assigned (by minimisation method) to 1% testosterone gel or placebo gel daily for 12 months, with participants and study staff masked to intervention all...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research